Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syn2bioWAR:S2B +1.88%11 PB Ratio is 42.62 as of Jul. 14, 2026. GuruFocus rates WAR:S2B with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,228 Biotechnology companies, Syn2bio ranks worse than 97.07% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-14), Syn2bio's share price is zł81.40. Syn2bio's Book Value per Share for the quarter that ended in Sep. 2025 was zł1.91. Hence, Syn2bio's PB Ratio of today is 42.62.
The historical rank and industry rank for Syn2bio's PB Ratio or its related term are showing as below:
WAR:S2B'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 42.62
Current: 42.62
During the past 3 years, Syn2bio's highest PB Ratio was 42.62. The lowest was 0.00. And the median was 0.00.
WAR:S2B's PB Ratio is ranked worse than 97.07% of 1228
companies
in the Biotechnology industry
Industry Median: 2.885
vs WAR:S2B: 42.62
During the past 12 months, Syn2bio's average Book Value Per Share Growth Rate was -11.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Syn2bio PB Ratio Related Terms
Syn2bio PB Ratio Historical Data
* Premium members only.
The historical data trend for Syn2bio's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syn2bio PB Ratio Chart
Syn2bio Annual Data
Trend
Sep23
Sep24
Sep25
PB Ratio
0.00
0.00
0.00
Syn2bio Semi-Annual Data
Sep23
Sep24
Sep25
PB Ratio
0.00
0.00
0.00
WAR:S2B vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Syn2bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syn2bio PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Syn2bio's PB Ratio distribution charts can be found below:
* The bar in red indicates where Syn2bio's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Syn2bio's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Syn2bio (WAR:S2B) has a PB Ratio of 42.62 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Syn2bio and its competitors. According to the industry distribution chart, Syn2bio ranks #1192 out of 1228 companies in the Biotechnology industry, placing it in the top 97.1%.
Is Syn2bio's PB Ratio too high?
Syn2bio's current PB Ratio is 42.62. The Biotechnology industry median PB Ratio is 2.89. Syn2bio's value of 42.62 is 1377.3% above this industry median. Based on the distribution chart, Syn2bio ranks #1192 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Syn2bio has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Syn2bio's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Syn2bio ranks #1192 out of 1228 companies for PB Ratio. This places Syn2bio in the lower half of its industry. The industry median PB Ratio is 2.89. Syn2bio's value of 42.62 is 1377.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.89, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syn2bio's current PB Ratio of 42.62 is 1377.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Syn2bio and its competitors. For the Biotechnology industry, the median PB Ratio is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syn2bio's current PB Ratio is 42.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syn2bio stock overvalued right now?
Syn2bio (WAR:S2B) has a current PB Ratio of 42.62. The current PB Ratio is 42.62 and 1377.3% above the Biotechnology industry median of 2.89. Syn2bio's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Syn2bio (WAR:S2B), the current PB Ratio is 42.62 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Syn2bio SA is a Polish biotech company that develops radiopharmaceuticals. It specializes in developing a cardiac biomarker for diagnosing heart conditions like coronary artery disease through myocardial perfusion imaging. The company's flagship product is the SYN2 cardiotracer. It is applied in the detection of perfusion disorders, evaluation of patients after myocardial infarction or with ischemic heart disease, and assessment of atherosclerotic changes in coronary arteries.
11GF Score
Get the complete analysis for WAR:S2B
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:S2B has been successfully added to your 
